Back to Newsroom

Apogenix Enters into Cooperation with R-Biopharm to Develop Companion Diagnostic Tests for Immuno-Oncology Candidate APG101

HEIDELBERG, Germany, July 28, 2015 /PRNewswire/ — Apogenix, a next generation immuno-oncology company, announced today that it has entered into an agreement with R-Biopharm, a global provider of innovative clinical diagnostics, to develop companion diagnostic tests for Apogenix’ lead drug candidate APG101. APG101 is a CD95 ligand inhibitor which restores the body’s immune response against tumors and inhibits invasive tumor cell growth. The drug candidate is being developed for the treatment of solid tumors and malignant hematological diseases.

Click here to read more